Home › Funds › Medicxi Ventures Management (Jersey) Ltd › PHAT

Medicxi Ventures Management (Jersey) Ltd position in PHAT

PHATHOM PHARMACEUTICALS INC · Health Care

Medicxi Ventures Management (Jersey) Ltd reported holding 7,464,572 shares of PHAT (PHATHOM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$54.5M, representing 43.02% of its reported portfolio and ranking #1 among its reported holdings. Medicxi Ventures Management (Jersey) Ltd has disclosed PHAT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)7.46M sh
Reported value held$54.49M
Portfolio Weight43.02%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Medicxi Ventures Management (Jersey) Ltd's PHAT position evolved

Medicxi Ventures Management (Jersey) Ltd first disclosed a stake in PHAT in Q3 2023 at 3,760,869 shares (US$39.0M). The position peaked in Q3 2024 at 7,464,572 shares, worth US$135.0M. Across 13 filings, Medicxi Ventures Management (Jersey) Ltd increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 11 time(s). The most recent filing (Q3 2026) shows 7,464,572 shares valued at US$54.5M. Notable position changes include a 98% increase in Q1 2024 (shares fell 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.76M $39.00M New
Q4 2023 3.76M $34.34M Hold
Q1 2024 7.46M $79.27M Add
Q2 2024 7.46M $76.89M Hold
Q3 2024 7.46M $134.96M Hold
Q4 2024 7.46M $60.61M Hold
Q1 2025 7.46M $46.80M Hold
Q2 2025 7.46M $71.59M Hold
Q3 2025 7.46M $87.86M Hold
Q4 2025 7.46M $123.84M Hold
Q1 2026 7.46M $82.93M Hold
Q2 2026 7.46M $80.99M Hold
Q3 2026 7.46M $54.49M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PHAT and 13F data

PHAT (PHATHOM PHARMACEUTICALS INC) is a Health Care company. 29 other funds we track also report a position in PHAT — the largest reported positions include Frazier Life Sciences Management, L.P. (US$135.3M), Carlyle Group Inc. (US$25.5M), NEA Management Company, LLC (US$21.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PHAT

All PHAT fund holders →

FAQ

How long has Medicxi Ventures Management (Jersey) Ltd held PHAT?

Medicxi Ventures Management (Jersey) Ltd has disclosed PHAT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Medicxi Ventures Management (Jersey) Ltd's current position in PHAT?

As of Q3 2026, Medicxi Ventures Management (Jersey) Ltd holds 7.46M shares of PHAT (PHATHOM PHARMACEUTICALS INC), valued at $54.49M, representing 43.02% of its reported portfolio and ranking #1.

Has Medicxi Ventures Management (Jersey) Ltd been buying or selling PHAT?

In the latest 13F filing (Q3 2026), Medicxi Ventures Management (Jersey) Ltd held unchanged its position in PHAT. The position peaked in Q3 2024 at 7.46M shares.

Which other funds hold PHAT?

Other major institutional holders of PHAT include Frazier Life Sciences Management, L.P., Carlyle Group Inc., NEA Management Company, LLC, among 29 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.